The aim of the study was to compare under in vivo conditions the new polyamide (Polyflux 160, Gambro) and cuprammonium-rayon dialyzers (AM-FP-17, Asahi; Clirans SE15NL, Terumo) with the polysulfone dialyzer (F60, Fresenius) regarding their permeability for beta-2-microglobulin (11.8 kD), retinol binding protein (21 kD), alpha-1-microglobulin (26.7 kD), alpha-1-glycoprotein (41 kD), alpha-1-antitrypsin (54 kD), albumin (66.3 kD) and transferrin (90 kD). The marker substances were measured by nephelometry or radioimmunoassay. To evaluate the membrane permeability, sieving coefficients 20 min after the start of hemodialysis were calculated using the concentration in the afferent and efferent blood line and in the ultrafiltrate. To get an idea about convective protein loss during a hemofiltration session, the values were computed in milligrams per 20 liters ultrafiltrate. Concerning the permeability of beta-2-microglobulin, the F60, AM-FP-17 and the Polyflux 160 hemofilter were comparable. In the molecular weight range of 20-60 kD both synthetic hemofilters were nearly impermeable. However, the cuprammonium-rayon dialyzers showed in this range a higher cutoff. The calculated albumin and transferrin loss is lower than those of CAPD patients or patients with nephrotic syndrome.

Keywords:
Permeability, Low-molecular-weight proteins, High-flux membranes, Hemodialysis
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.